Atalanta Therapeutics

A Boston lab is doing the thing RNAi wasn't supposed to do

On a January morning in 2025, a 46-person company on Sleeper Street in Boston's Seaport closed a $97 million Series B that was, in the polite language of biotech, "oversubscribed." Translation: more investors wanted in than there was room for. The reason was not modest. Atalanta Therapeutics says it can do something the entire RNA interference field spent two decades calling impractical - silence a disease-causing gene across the whole brain and spinal cord, and keep it silenced.

RNAi drugs already exist. Several are approved. Nearly all of them work in the liver, which is convenient, because the liver is where these molecules naturally pile up. The brain, by contrast, sits behind a blood-brain barrier that treats most drugs like uninvited guests. Atalanta picked the brain on purpose.

Knowing the bad gene is easy. Reaching it is the whole job.

Genetics has gotten remarkably good at naming culprits. We know the gene behind Huntington's disease. We know that mutations in KCNT1 drive a severe form of childhood epilepsy. The intellectual problem - which gene to turn down - is, in many cases, solved.

The engineering problem is not. A gene-silencing molecule has to survive the journey, cross into neural tissue, spread far enough to matter, hit the right target and not others, and last long enough that patients aren't dosed constantly. Get distribution wrong and you've treated a thumbnail of cortex while the rest of the brain carries on undisturbed. The field's quiet frustration was never "what do we silence." It was "how do we get there, everywhere, and stay."

Three scientists, one branched molecule, and a Nobel in the room

Atalanta was founded in 2018 out of the RNA Therapeutics Institute at UMass Chan Medical School. The founders are not hobbyists. One of them, Craig Mello, shared the 2006 Nobel Prize in Physiology or Medicine for co-discovering RNA interference in the first place. The others, Anastasia Khvorova and Neil Aronin, have spent careers on the chemistry and the clinical biology of getting RNA into hard places.

Their bet had a shape, literally. Instead of a single siRNA strand, they joined two together into a branched architecture they call di-siRNA - divalent small interfering RNA. The wager was that this design would travel farther through neural tissue and silence its target for the long haul. It is the kind of idea that sounds simple in a sentence and consumes years in a lab.

The founding bench. Between them, decades of RNAi - and the patience to aim it at the brain.

One platform, a pipeline that fans out from it

The asset is the di-siRNA platform; the pipeline is what you build with it. Atalanta is advancing wholly-owned programs while letting big pharma partners apply the same chemistry to their own targets. The two lead programs are the ones it intends to take into humans first.

Same molecule, many destinations. The platform is the factory; the programs are the product line.

Money is a vote. Atalanta has collected a few.

Belief is cheap; capital is not. The case for Atalanta is written partly in who has written checks and partly in what those checks are meant to buy - namely, the leap from animal data to the first human trials.

The Series B reads like a who's who of life-science investors: EQT Life Sciences and Sanofi Ventures co-led, joined by RiverVest, the Novartis Venture Fund, abrdn, Pictet Alternative Advisors, Mirae Asset, the GHR Foundation, and returning backer F-Prime Capital. Pharma partners Biogen and Genentech were there at the start. That is a lot of independent due-diligence teams reaching the same conclusion.

Why bother with the hardest organ in the body

Neurological disease is the category medicine has lost to most often. Huntington's is fatal and inherited. Severe genetic epilepsies arrive in childhood. The list of conditions where we know the gene but cannot yet do anything about it is long, and most of those genes live behind the blood-brain barrier.

Atalanta's stated reason for existing is unfussy: it was created to address the urgent global need for treatments of neurological diseases. The ambition underneath that sentence is large. If a single platform can be pointed at one CNS target after another, the work stops being "cure this one disease" and becomes "build the road that reaches all of them."

The next chapter is written in patients, not press releases

Here is the honest caveat a skeptical reader deserves: nothing here is approved yet. Preclinical data is a promise, not a proof, and the graveyard of biotech is full of molecules that worked beautifully in mice. The next few years - the first human trials in KCNT1 epilepsy and Huntington's - are where the di-siRNA thesis either holds or doesn't.

But return to that January morning in the Seaport. A small company with a Nobel laureate among its founders convinced a crowded room of investors that the brain - the target everyone else routed around - is reachable. The barrier that defined the field's limits is now, in Atalanta's telling, just an address. Whether the postcards arrive is the question the clinic will answer. The bet has already been placed.